One of the buzzwords that is currently in vogue in the investment community is biotechnology. This is a broad-based field that covers technological applications in any biological system, meaning humans, animals, agriculture, and medicines. This is a booming science and the investment field offers many opportunities for wealth accumulation.

If you don't want to spend countless hours trying to understand not just financials, but scientific and technical jargon that biotech companies harbor, exchange-traded funds (ETFs) may be the better choice for investing in the biotechnology industry.

An ETF is similar to buying a share of a company, but instead of getting one particular company you're investing in a bundle of companies within a particular field or specialty. It's a great way to invest in something you believe in while still hedging your bets and having a bit of diversity.

Analyst upgrades:

• Jefferies upgraded MSC Industrial (NYSE:MSM) to Buy from Hold after meeting with management as they believe shares are attractive at current levels. The firm raised their target price to $44 from $32.
  
• UBS upgraded DuPont Fabros (NYSE:DFT) to Buy from Neutral and raised their target to $7 from $2. The firm believes DuPont Fabros will receive a waiver on its CH1 Construction loan for at least a year.
  
• Royal Bank of Scotland upgraded Credit Suisse (NYSE:CS) to Buy from Hold to reflect the company's derisking of its trading book.
• Smith & Nephew (NYSE:SNN) was upgraded to Buy from Neutral at Goldman and added to the Conviction Buy List; Cigna (NYSE:CI) was also added to the Conviction Buy List.
  
• Affymetrix (NASDAQ:AFFX) was raised to Equal Weight from Underweight at Morgan Stanley.
  
• Airtran Holdings (NYSE:AAI) was upgraded to Buy from Hold at Jesup & Lamont.

Analyst upgrades:

• Keefe Bruyette upgraded shares of Colonial Bancgroup (NYSE: CNB) to Outperform from Market Perform on valuation following the recent weakness and believes the company will be eligible to receive TARP funds. Morgan Stanley believes the company's valuation adequately reflects risk to the loan portfolio; the firm raised shares to Equal Weight from Underweight.
• Merrill upgraded Ericsson (NASDAQ: ERIC) and ASML Holding (NASDAQ: ASML) to Buy from Underperform and believes their valuation reflects the worst-case for bad news.
• Oppenheimer upgraded Trimble Navigation to Outperform from Perform on valuation as they believe the company's long-term growth story is intact.
• Celestica (NYSE: CLS) was upgraded to Sector Outperformer from Sector Performer at CIBC.
• KeyCorp (NYSE: KEY) was added to Goldman's Conviction Buy List.
• Wachovia raised EastGroup Properties (NYSE: EGP) to Outperform from Market Perform.

Analyst downgrades:

• UBS cut Barclays (NYSE: BCS) to Neutral from Buy as they believe capital raises could negatively impact earnings and that the dividend is likely to be cut.
• JP Morgan downgraded Discovery Holdings (NASDAQ: DISCA) to Underweight from Neutral based on valuation and the deteriorating economic outlook.
• Friedman Billings downgraded shares of Janus Capital (NYSE: JNS) to Underperform from Market Perform and lowered its target to $7 from $23 as they see further risk to the downside following the company's weaker-than-expected results.
• LKQ Corp (NASDAQ: LKQX) was cut to Sector Perform from Outperform at RBC Capital.
• Affymetrix (NASDAQ: AFFX) was lowered to Sell from Hold at Deutsche Bank.
• RightNow Tech (NASDAQ: RNOW) was downgraded at Baird to Neutral from Outperform.

Analyst upgrades:

• Baird upgraded Buffalo Wild Wings (NASDAQ: BWLD) to Outperform from Neutral following strong Q2 results as they expect comps momentum, operating leverage, and potentially favorable chicken wing costs to support healthy trends in 2H08.
  
• RBC Capital upgraded Myriad Genetics (NASDAQ: MYGN) to Outperform from Sector Perform citing solid core molecular diagnostics growth and increased confidence that the spin-out will generate better shareholder value.

Analyst downgrades:

• Citigroup downgraded shares of Wyeth (NYSE: WYE) to Sell from Hold following the disappointing bapineuzumab data and lowered their target to $39 from $49.
• Molson Coors (NYSE: TAP) was downgraded to Neutral from Overweight at JP Morgan.
  
• UBS lowered Affymetrix (NASDAQ: AFFX) and Sepracor (NASDAQ: SEPR) to Neutral from Buy.
  
• Sony (NYSE: SNE) was downgraded to Underweight from Neutral at HSBC.

Analyst initiations:

• Citigroup initiated Intercontinental Exchange (NYSE: ICE) with a Hold rating and $112 target. The firm believes regulatory concerns and a potential deceleration in energy trading volumes could limit upside in the stock near-term.
  
• Banc of America assumed Walgreen Co. (NYSE: WAG) with a Buy rating and $38 target and believes fewer new pharmacies openings removes an impediment to higher ROIC.

Northwest (NYSE:NWA) is up 10% on news of its merger with Delta (NYSE:DAL).

Compuware (NASDAQ:CPWR) is up almost 19% on news of higher-than-expected earnings.

Crocs (NADSAQ:CROX) is down 28% after lowering its earnings forecast.

Affymetrix (NASDAQ:AFFX) is off 27% after dropping its guidance for the next quarter.

Stocks may trade differently in the pre-market than they do in the regular session.

Douglas A. McIntyre is an editor at 247wallst.com.

Blockbuster (NYSE:BBI) was cut to "neutral" at JPMorgan according to 24/7 Wall St. The financial website also reports that EMC Corp. (NYSE:EMC) was cut to "hold" from "buy" at Citigroup.

Citigroup downgraded Emulux (NYSE:ELX) from "buy" to "sell" according to Briefing.com. The newswire also reports that Bear Stearns downgraded Affymetrix (NASDAQ:AFFX) to "underperform" from "out perform"

Douglas A. McIntyre is an editor at 24/7 Wall St.

MOST NOTEWORTHY: EMC Corp, Emulex, VCG Holding and Conexant were today's noteworthy downgrades:

• Citigroup downgraded shares of EMC Corp (NYSE: EMC) to hold from buy and Emulex (NYSE: ELX) to sell from buy and lowered its targets to $17 from $22 and to $12 from $20, respectively, to reflect their more cautious stance on the storage space after channel checks indicated a broadly softening demand environment, most notably for 'higher ticket' items.
  
• Merriman downgraded shares of VCG Holding (NASDAQ:VCGH) to neutral from buy following the Q4 miss, as they believe acquisitions could slow in the near-term. They prefer to move to the sidelines until the company's outlook improves.
  
• Oppenheimer downgraded Conexant (NASDAQ: CNXT) to perform from outperform as they believe the CEO departure could interrupt the company's turnaround.

OTHER DOWNGRADES:

• Hercules Offshore (NASDAQ: HERO) was cut to hold from buy at Deutsche Bank.
  
• JP Morgan downgraded Blockbuster (NYSE: BBI) to neutral from overweight.
  
• Affymetrix (NASDAQ: AFFX) was downgraded to underperform from peer perform at Bear.

Illumina (NASDAQ: ILMN): Settles patent lawsuit with major rival Affymetrix (NASDAQ: AFFX). Shares trade up to $75.20 against 52-week low of $28.11.

Kinross Gold (NYSE: KGC): Price of gold and gold producers just keeps rising. Stock moves up to $22.86 from 52-week low of $9.87.

Yamana Gold (NYSE: AUY): Gold again. Rises to $16.30 from 52-week low of $8.40.

PepsiCo (NYSE: PEP): Soft-drinks sales aren't hurt by recessions, as far as anyone knows. Trades up to $79.79 from 52-week low of $61.89.

Douglas A. McIntyre is an editor at 247wallst.com.